🟢 Humacyte is trading 5.3% up in pre-market with no identified catalyst

Humacyte is trading at $0.47, up 5.31% in pre-market; no new company-specific announcement or clear catalyst was found for October 28.

• Latest company news was the October 23 report of positive interim Phase 3 V012 results, predating this move.
• Broader markets are mixed, and available evidence does not establish a market-wide reason for the rise.
• Humacyte rose 11.41% on October 27 after declines on October 26; prior clinical news may remain background context, but evidence does not confirm it caused either move.